The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (update 2017)2017 Available from: http://www.goldcopd.org/Accessed February 20, 2017
   Google Scholar
• MennPHeinrichJHuberRMKORA Study GroupDirect medical costs of COPD – an excess cost approach based on two population-based studiesRespir Med2012106454054822100535
   PubMed Web of Science ®Google Scholar
• WackerMEJörresRASchulzHCOSYCONET-ConsortiumDirect and indirect costs of COPD and its comorbidities: results from the German COSYCONET studyRespir Med2016111394626725462
   PubMed Web of Science ®Google Scholar
• FordESMurphyLBKhavjouOGilesWHHoltJBCroftJBTotal and state-specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020Chest20151471314525058738
   PubMed Web of Science ®Google Scholar
• JanssonSABackmanHStenlingALindbergARönmarkELundbackBHealth economic costs of COPD in Sweden by disease severity – has it changed during a ten years period?Respir Med2013107121931193823910072
   PubMed Web of Science ®Google Scholar
• European Respiratory SocietyThe European Lung White Book2nd revised edSheffieldEuropean Respiratory Society2013
   Google Scholar
• GershonASGuanJVictorJCGoldsteinRToTQuantifying health services use for chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013187659660123328526
   PubMed Web of Science ®Google Scholar
• McLeanSHoogendoornMHoogenveenRTProjecting the COPD population and costs in England and Scotland: 2011 to 2030Sci Rep201663189327583987
   PubMed Web of Science ®Google Scholar
• VoglMLeidlRInforming management on the future structure of hospital care: an extrapolation of trends in demand and costs in lung diseasesEur J Health Econ201617450551726032899
   PubMed Web of Science ®Google Scholar
• HillasGPerlikosFTsiligianniITzanakisNManaging comorbidities in COPDInt J Chron Obstruct Pulmon Dis2015109510925609943
   PubMed Web of Science ®Google Scholar
• HuberMBWackerMEVogelmeierCFLeidlRComorbid influences on generic health-related quality of life in COPD: a systematic reviewPLoS One2015107e013267026168154
   PubMed Web of Science ®Google Scholar
• WackerMEJörresRAKarchACOSYCONET study groupRelative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studiesRespir Res20161718127405652
   PubMed Web of Science ®Google Scholar
• DivoMCoteCde TorresJPBODE Collaborative GroupComorbidities and risk of mortality in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012186215516122561964
   PubMed Web of Science ®Google Scholar
• MillerJEdwardsLDAgustíAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) InvestigatorsComorbidity, systemic inflammation and outcomes in the ECLIPSE cohortRespir Med201310791376138423791463
   PubMed Web of Science ®Google Scholar
• GershonASMecredyGCGuanJVictorJCGoldsteinRToTQuantifying comorbidity in individuals with COPD: a population studyEur Respir J2015451515925142481
   PubMed Web of Science ®Google Scholar
• JanssonSABackmanHRonmarkELundbäckBLindbergAHospitalization due to co-morbid conditions is the main cost driver among subjects with COPD-a report from the population-based OLIN COPD studyCOPD201512438138925415366
   PubMedGoogle Scholar
• WestneyGForemanMGXuJHenriques KingMFlenaughERustGImpact of comorbidities among Medicaid enrollees with chronic obstructive pulmonary disease, United States, 2009Prev Chronic Dis201714E3128409741
   PubMed Web of Science ®Google Scholar
• HuberMBWackerMEVogelmeierCFLeidlRExcess costs of comorbidities in chronic obstructive pulmonary disease: a systematic reviewPLoS One2015104e012329225875204
   PubMed Web of Science ®Google Scholar
• Simon-TuvalTScharfSMMaimonNBernhard-ScharfBJReuveniHTarasiukADeterminants of elevated healthcare utilization in patients with COPDRespir Res201112721232087
   PubMed Web of Science ®Google Scholar
• SchwarzkopfLWackerMErtlJHapfelmeierJLarischKLeidlRImpact of chronic ischemic heart disease on the health care costs of COPD patients – an analysis of German claims dataRespir Med201611811211827578479
   PubMed Web of Science ®Google Scholar
• SchwabPDhamaneADHopsonSDImpact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare populationInt J Chron Obstruct Pulmon Dis20171273574428260880
   PubMed Web of Science ®Google Scholar
• DenizSŞengülAAydemirYÇeldir EmreJÖzhanMHClinical factors and comorbidities affecting the cost of hospital-treated COPDInt J Chron Obstruct Pulmon Dis2016113023303027980399
   PubMed Web of Science ®Google Scholar
• DingBSmallMBergströmGHolmgrenUCOPD symptom burden: impact on health care resource utilization, and work and activity impairmentInt J Chron Obstruct Pulmon Dis20171267768928260874
   PubMed Web of Science ®Google Scholar
• FooJLandisSHMaskellJContinuing to confront COPD International Patient Survey: economic impact of COPD in 12 countriesPLoS One2016114e015261827092775
   PubMed Web of Science ®Google Scholar
• SmallMHolbrookTWoodRMullerovaHNayaIPunekarYSPrevalence and burden of dyspnoea among COPD patients in JapanInt J Clin Pract201670867668127396989
   PubMed Web of Science ®Google Scholar
• KarchAVogelmeierCWelteTCOSYCONET Study GroupThe German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baselineRespir Med2016114273727109808
   PubMed Web of Science ®Google Scholar
• JörresRAWelteTBalsRKochASchnoorMVogelmeierCEinfluss systemischer Manifestationen und Komorbiditäten auf den klinischen Zustand und den Verlauf bei COPD [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease – an overview of the cohort study COSYCONET]Dtsch Med Wochenschr201013510446449 German20198540
   PubMed Web of Science ®Google Scholar
• QuanjerPHStanojevicSColeTJERS Global Lung Function InitiativeMulti-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEur Respir J20124061324134322743675
   PubMed Web of Science ®Google Scholar
• KarlFMHolleRBalsRCOSYCONET Study GroupCosts and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patientsRespir Res20171816028416015
   PubMed Web of Science ®Google Scholar
• BockJOBrettschneiderCSeidlHCalculation of standardised unit costs from a societal perspective for health economic evaluationGesundheitswesen20157715361 German25025287
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics MethodologyGuidelines for ATC Classification and DDD Assignment 2010OsloWHOCC2009
   Google Scholar
• Wissenschaftliches Institut der AOK (WIdO) Available from: http://wido.de/arzneimittel.htmlAccessed May 20, 2011 German
   Google Scholar
• Federal Statistical OfficeStatistical Yearbook 2013 for the Federal Republic of GermanyWiesbadenFederal Statistical Office2014
   Google Scholar
• Institute for Employment Research (IAB) of the German Federal Employment Agency (BA)IAB brief reports no. 18NurembergIAB2014
   Google Scholar
• JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD Assessment TestEur Respir J200934364865419720809
   PubMed Web of Science ®Google Scholar
• PutchaNPuhanMADrummondMBA simplified score to quantify comorbidity in COPDPLoS One2014912e11443825514500
   PubMed Web of Science ®Google Scholar
• BolandMRKruisALTsiachristasACost-effectiveness of integrated COPD care: the RECODE cluster randomised trialBMJ Open2015510e007284
   Web of Science ®Google Scholar
• BolandMRTsiachristasAKruisALChavannesNHRutten-van MolkenMPThe health economic impact of disease management programs for COPD: a systematic literature review and meta-analysisBMC Pulm Med2013134023819836
   PubMed Web of Science ®Google Scholar
• McPhailSMMultimorbidity in chronic disease: impact on health care resources and costsRisk Manag Healthc Policy2016914315627462182
   PubMed Web of Science ®Google Scholar
• WackerMEJörresRAKarchAAssessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbiditiesBMC Pulm Med20161617027160582
   PubMed Web of Science ®Google Scholar
• ManninoDMHiguchiKYuTCEconomic burden of COPD in the presence of comorbiditiesChest2015148113815025675282
   PubMed Web of Science ®Google Scholar
• InoueDWatanabeROkazakiRCOPD and osteoporosis: links, risks, and treatment challengesInt J Chron Obstruct Pulmon Dis20161163764827099481
   PubMed Web of Science ®Google Scholar
• OkazakiRWatanabeRInoueDOsteoporosis associated with chronic obstructive pulmonary diseaseJ Bone Metab201623311112027622174
   PubMedGoogle Scholar
• ErdalMJohannessenAAskildsenJEEaganTGulsvikAGrøonsethRProductivity losses in chronic obstructive pulmonary disease: a population-based surveyBMJ Open Respir Res201411e000049
   PubMedGoogle Scholar
• MiravitllesMHuertaAValleMClinical variables impacting on the estimation of utilities in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20151036737725733826
   PubMed Web of Science ®Google Scholar
• PunekarYSWurstKShuklaAResource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: a retrospective cohort studyCOPD201512326727525093809
   PubMedGoogle Scholar
• DesleeGBurgelPREscamillaRImpact of current cough on health-related quality of life in patients with COPDInt J Chron Obstruct Pulmon Dis2016112091209727695305
   PubMed Web of Science ®Google Scholar
• WackerMHolleRHeinrichJThe association of smoking status with healthcare utilisation, productivity loss and resulting costs: results from the population-based KORA F4 studyBMC Health Serv Res20131327823866993
   PubMed Web of Science ®Google Scholar
• LuckeTHerreraRWackerMCOSYCONET-ConsortiumSystematic analysis of self-reported comorbidities in large cohort studies – a novel stepwise approach by evaluation of medicationPLoS One20161110e016340827792735
   PubMed Web of Science ®Google Scholar
• EvansCCrawfordBPatient self-reports in pharmacoeconomic studies. Their use and impact on study validityPharmacoeconomics199915324125610537432
   PubMed Web of Science ®Google Scholar
• SeidlHMeisingerCWendeRHolleREmpirical analysis shows reduced cost data collection may be an efficient method in economic clinical trialsBMC Health Serv Res20121231822978572
   PubMed Web of Science ®Google Scholar
• VanfleterenLESpruitMAWoutersEFFranssenFMManagement of chronic obstructive pulmonary disease beyond the lungsLancet Respir Med201641191192427264777
   PubMed Web of Science ®Google Scholar
• BriggsABakerTRisebroughNADevelopment of the galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort modelMed Decis Making201737446948027317436
   PubMed Web of Science ®Google Scholar
• HoogendoornMFeenstraTLAsukaiYPatient heterogeneity in health economic decision models for chronic obstructive pulmonary disease: are current models suitable to evaluate personalized medicine?Value Health201619680081027712708
   PubMed Web of Science ®Google Scholar
• AsukaiYBaldwinMFonsecaTGrayAMungapenLPriceDImproving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approachPharmacoeconomics201331215116123329431
   PubMed Web of Science ®Google Scholar